Twist Bioscience, synthetic biology and genomics company, agreed to acquire Abveris, an antibody discovery services company, for $190m. “The addition of the Abveris discovery platform is a natural fit with Twist as it will complement and extend our biopharma antibody capabilities into mouse-based discovery and screening. There are three key approaches to antibody discovery: synthetic libraries, which is the specialty of Twist; in vivo discovery through animal models; and artificial intelligence models. With the anticipated acquisition of Abveris, Twist will have expertise in each, creating a robust antibody design, discovery and screening organization to serve both our partners and our internal pipeline,” Emily M. Leproust, Twist Bioscience CEO and Co-Founder.